%0 Conference Paper
%A Biel, Davina
%A Steward, Anna
%A Dewenter, Anna
%A Dehsarvi, Amir
%A Zhu, Zeyu
%A Roemer-Cassiano, Sebastian
%A Frontzkowski, Lukas
%A Hirsch, Fabian
%A Brendel, Matthias
%A Franzmeier, Nicolai
%T Plasma p‐tau217 as a suitable biomarker for monitoring cognitive changes in Alzheimer’s disease
%J Alzheimer's and dementia
%V 21
%N Suppl 8
%@ 1552-5260
%M DZNE-2025-01502
%P e110180
%D 2025
%X With the approval of anti-amyloid therapies in Alzheimer's disease (AD), surrogate biomarkers are urgently needed to monitor treatment effects that translate into clinical benefits. Candidate biomarkers, including amyloid-PET, tau-PET, plasma phosphorylated tau (p-tau), and MRI-assessed atrophy, capture core pathophysiological changes in AD. While cross-sectional biomarker assessments are critical for diagnosis and staging, biomarker change rates may better reflect disease dynamics, making them more suitable for monitoring treatment efficacy. Therefore, we determined which biomarker most effectively tracks cognitive changes in AD, identifying those best suited for efficient monitoring of disease-modifying treatments.We leveraged ADNI (N = 108) and A4 (N = 151) participants with longitudinal AD biomarker data (global amyloid-PET, temporal meta tau-PET, plasma p-tau217, MRI-assessed cortical thickness in the AD signature region) together with cognitive assessments (ADNI: MMSE, ADAS13, CDR-SB; A4: MMSE, PACC). Linear mixed models were used to calculate change rates for biomarkers and cognition. To test whether biomarker changes track cognitive decline, linear models were applied, to test biomarker change rates as a predictor of cognitive change rates. Standardized beta values from bootstrapped linear models were extracted to compare the strengths of correlations between biomarkers and cognitive decline. For non-parametric comparisons, 95
%B Alzheimer’s Association International Conference
%C 27 Jul 2025 - 31 Jul 2025, Toronto (Canada)
Y2 27 Jul 2025 - 31 Jul 2025
M2 Toronto, Canada
%K Humans
%K Alzheimer Disease: diagnostic imaging
%K Alzheimer Disease: pathology
%K Male
%K Female
%K tau Proteins: blood
%K Biomarkers: blood
%K Aged
%K Magnetic Resonance Imaging
%K Positron-Emission Tomography
%K Longitudinal Studies
%K Aged, 80 and over
%K Brain: diagnostic imaging
%K Brain: pathology
%K Amyloid beta-Peptides
%K tau Proteins (NLM Chemicals)
%K Biomarkers (NLM Chemicals)
%K Amyloid beta-Peptides (NLM Chemicals)
%F PUB:(DE-HGF)1 ; PUB:(DE-HGF)16
%9 AbstractJournal Article
%$ pmid:41433469
%2 pmc:PMC12725594
%R 10.1002/alz70862_110180
%U https://pub.dzne.de/record/283095